Dashboard MRSA
Repurposing candidates for MRSA
Methicillin-resistant Staphylococcus aureus
Approved medicines with AI-predicted activity ≥40% against MRSA, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 860
- Existing antimicrobials set aside
- 117
- Needing review
- 72
- Repurposing candidates
- 671
Repurposing candidates for MRSA
AI prediction · nothing measuredAll 671 repurposing candidates for MRSA.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- RisdiplamExisting use: Atrophy, Proximal spinal muscular atrophy, Spinal muscular atrophy54.8% AI-predicted activityagainst MRSA33 registered studies
- Amphotericin BExisting use: Aspergillosis, Candidiasis, Cryptococcal meningitis and 7 more54.7% AI-predicted activityagainst MRSA50+ registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension54.7% AI-predicted activityagainst MRSA50+ registered studies
- AlprazolamExisting use: Anxiety, Anxiety disorder, Generalized anxiety disorder and 1 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- RevefenacinExisting use: Airway obstruction, Chronic obstructive pulmonary disease54.6% AI-predicted activityagainst MRSA20 registered studies
- CobicistatExisting use: HIV infection, HIV-1 infection, Infection54.6% AI-predicted activityagainst MRSA50+ registered studies
- ErdafitinibExisting use: Bladder tumor, Cancer, Neoplasm and 2 more54.6% AI-predicted activityagainst MRSA43 registered studies
- AvanafilExisting use: Erectile dysfunction, Impotence54.5% AI-predicted activityagainst MRSA24 registered studies
- Conivaptan HydrochlorideExisting use: Cardiovascular disease, Heart failure54.5% AI-predicted activityagainst MRSA21 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more54.4% AI-predicted activityagainst MRSA50+ registered studies
- OdevixibatExisting use: Intrahepatic cholestasis54.4% AI-predicted activityagainst MRSA13 registered studies
- Elacestrant HydrochlorideExisting use: Breast neoplasm, Male breast carcinoma54.3% AI-predicted activityagainst MRSA2 registered studies
- IxabepiloneExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 2 more54.1% AI-predicted activityagainst MRSA50+ registered studies
- DeflazacortExisting use: Duchenne muscular dystrophy, Muscular dystrophy, Qualitative or quantitative defects of dysferlin54.1% AI-predicted activityagainst MRSA24 registered studies
- Nicardipine HydrochlorideExisting use: Cardiovascular disease, Hypertension54.1% AI-predicted activityagainst MRSA50+ registered studies
- FlurandrenolideExisting use: Skin disease54.0% AI-predicted activityagainst MRSA3 registered studies
- DifluprednateExisting use: Anterior uveitis, Eye inflammation, Inflammation54.0% AI-predicted activityagainst MRSA25 registered studies
- CanagliflozinExisting use: Diabetes mellitus, Type 2 diabetes mellitus54.0% AI-predicted activityagainst MRSA50+ registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.0% AI-predicted activityagainst MRSA27 registered studies
- DeucravacitinibExisting use: Psoriasis, Psoriasis vulgaris53.9% AI-predicted activityagainst MRSA50+ registered studies
- BetamethasoneExisting use: Airway obstruction, Eye inflammation, Hemorrhoid and 1 more53.9% AI-predicted activityagainst MRSA50+ registered studies
- DexamethasoneExisting use: Acne, Adrenal gland disease, Adrenal gland hyperfunction and 75 more53.9% AI-predicted activityagainst MRSA50+ registered studies